Capricor and Lonza Forge Groundbreaking Partnership to Combat DMD and COVID-19
Strategic Partnership Formed
Capricor Therapeutics has teamed up with Lonza, a global leader in biotechnology, to advance the development of CAP-1002. This collaboration marks a significant step towards bringing innovative cell therapy treatments to market. By combining their strengths, both companies aim to enhance the efficacy and reach of CAP-1002 for patients in need.
Expanding Manufacturing Capabilities
The partnership is set to boost Capricor’s manufacturing capacity, ensuring they can meet the demands of late-stage clinical trials and eventual commercialization. With Lonza’s robust infrastructure, Capricor can scale up production efficiently and maintain high-quality standards. This expansion is crucial for supporting ongoing research and future therapeutic launches.
Advanced Process Development
Process development for CAP-1002 will take place at Lonza’s state-of-the-art Houston center of excellence. This facility is renowned for its expertise in developing and manufacturing cutting-edge biologics. By leveraging Lonza’s advanced technologies, Capricor aims to optimize the production process, ensuring consistency and reliability in their therapeutic offerings.
Clinical Progress of CAP-1002
CAP-1002 has shown promising results in the HOPE-2 phase 2 clinical trial, demonstrating potential benefits for patients with Duchenne Muscular Dystrophy (DMD). Additionally, the therapy has received orphan drug designation from the FDA, highlighting its importance in treating rare diseases. Capricor is also exploring CAP-1002’s applications in addressing complications from COVID-19.
Lonza’s Role in Commercialization
Lonza brings a wealth of experience in technology transfer and commercializing biologics to the collaboration. Their proven track record ensures that CAP-1002 will be efficiently prepared for market launch. This partnership not only accelerates the development timeline but also enhances the global distribution capabilities of Capricor’s therapeutic solutions.
Conclusion
The collaboration between Capricor Therapeutics and Lonza represents a powerful alliance in the biotech industry. By combining their respective expertise, they are well-positioned to advance CAP-1002 towards successful commercialization. This partnership holds great promise for improving the lives of patients with DMD and potentially those affected by COVID-19 complications.
Read the full article here:
businessinsider.com